drugset / Trial / NCT05613803

Poly-unsaturated Fats for Improving Nasal Polyps and Asthma

NCT05613803

RandomizedParallel-groupDouble-blindTreatment

Summary

Asthma is a syndrome compromising many phenotypes including N-ERD (caused by increased 4-series leukotriene (LT) production). n-3 PUFA supplementation modulates 4-series LT and has anti-inflammatory effects. However, other than in a pilot study with dietary manipulation, the effects of N-ERD are unknown. The primary objective is to determine whether n-3 PUFA supplementation in people with N-ERD can improve asthma control using the asthma control questionnaire (ACQ-7). This is a placebo controlled randomised controlled parallel multicentre study with of 6g per day of PUFA for 6 months in people with N-ERD and poor asthma control

Timeline

Start
2023-10-09
Primary completion
2026-01-31
Completion
2026-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fish oil Other / unclassified 6 g Oral

Indications